Total body irradiation (TBI) institutional experience  by Fondevilla, A. et al.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S275–S281 S281
interval sections) and diagnostic MRI image fusion. CTV was left orbit using two 6MV wedges oblique-ﬁelds. A total dose of 27Gy
in 15 fractions was administered. Tolerance to treatment was adequate, with mild transient epiphora and conjunctivitis. Result:
two months after treatment there was a complete clinical and radiological response without any toxicity associated.
Conclusions. There are no data from randomized trials on which to base therapeutic decisions, however, numerous retrospective
studies show that RT offers excellent local control rates and cause-speciﬁc survival at doses up to 30Gy allowing preserve the
orbital integrity with very low risk of severe complications. Other treatment options include complete excision of small lesions,
intralesional interferon alpha or observation. Eradication of Chlamydia Psitttaci, whoseDNAhas been found in some conjunctival
MALT, with doxycycline, showed partial and even complete responses in some series.
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Purpose. Was analyzed our experience in patients with hematological diseases who underwent myeloablative transplant with
TBI and cyclophosphamide as part as the conditioning regimen.
Patients and methods. Retrospective study of 43 patients (17 female, 26 males) from October 2006 to December 2011 underwent
transplantation with TBI as part of the conditioning regimen (42 allogeneic transplant and 1 autologous transplant). The haema-
tological disease was acute leukaemie in 35 patients (81%), NHL in 3 (7%) and others in 5 patients (12%). The dose of TBI were
12Gy in 6 fractions, twice a day with an interval at least of 6h. No patient received more than 10Gy in lungs. The administration
of the treatment was performed on a linear accelerator, energy of 15MV a source to patient’s middle line distance of 5m. The
patients are inmovilized in supine position. The skin dose is increased using a large plastic screen (methacrylate) covering the
whole body and is placed approximately 10 cm from the patient, which acts as a source of scattered electrons. We analyzed the
incidence of acute transplant related toxicity (before day +90) and overall survival (OS), transplant related mortality (TRM) and
disease free survival (DFS). Results: Acute transplant toxicity incidence was: grade >3 mucositis 29 cases (67%), acute parotidis 7
cases (16%) and grade >3 nausea or vomit in 2 case (5%). Day +100 TRM, OS and DFS were 2%, 98% and 100% respectively. With a
median follow up of 44 months (range 1–85), 32 patients (74%) are alive and in complete remission of their underlying disease, 8
patients (19%) died of disease relapse or progression and 2 patients of TRM.
Conclusions. DFS and toxicity are successfully compared to literature data.
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